secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0000950170-25-027734
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q4 net loss narrows to $2.1M; latozinemab Phase 3 data expected Q4 2025
-------------------------------------------------------------------------------

- Q4 2024 net loss $2.1M ($0.02 loss per share) vs $41.4M loss ($0.49 loss) in Q4 2023, revenue $54.2M vs $15.2M.
- Cash, cash equivalents and investments $413.4M, expected to fund operations through 2026.
- Topline data from pivotal INFRONT-3 Phase 3 trial of latozinemab in FTD-GRN anticipated by Q4 2025.
- Enrollment in PROGRESS-AD Phase 2 trial of AL101/GSK4527226 in early Alzheimer's expected to complete by mid-2025.
- 2025 guidance: collaboration revenue $5-15M, R&D expense $175-185M, G&A $55-65M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017025027734/0000950170-25-027734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017025027734/alec-20250226.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-027734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer